Real-world adalimumab survival and discontinuation factors in hidradenitis suppurativa

被引:2
作者
Garbayo-Salmons, Patricia [1 ,2 ,17 ]
Vilarrasa, Eva [3 ]
Bassas-Vila, Julio [4 ]
Mora-Fernandez, Veronica [4 ]
Fuertes, Irene [5 ]
Luque-Luna, Mar [5 ]
Fornons-Servent, Rosa [6 ]
Martin-Ezquerra, Gemma [7 ]
Aguayo-Ortiz, Rafael Sergio [8 ]
Ceravalls, Joan [9 ]
Mollet, Jordi [10 ]
Tomas, Alvaro Gomez [10 ]
Masferrer, Emili [11 ]
Corral-Magana, Oriol [11 ]
Matas-Nadal, Clara [12 ]
del Estal, Jorge [13 ]
Bailon, Diana Fuertes [14 ]
Calvet, Joan [2 ,15 ]
Romani, Jorge [16 ]
机构
[1] Parc Tauli Hosp Univ, Inst Invest & Innovacio Parc Tauli I3PT CERCA, Dermatol Dept, Sabadell, Spain
[2] Univ Autonoma Barcelona, Dept Med, Sabadell, Spain
[3] Hosp Santa Creu i St Pau, ENT Dept, Barcelona, Spain
[4] Hosp Germans Trias i Pujol, Dept Cardiol, Badalona, Barcelona, Spain
[5] Hosp Clin Barcelona, Dermatol Dept, Barcelona, Spain
[6] Hosp Bellvitge Princeps Espanya, Dermatol Dept, Barcelona, Spain
[7] Hosp Mar, Dermatol Dept, Barcelona, Spain
[8] Hosp Arnau Vilanova, Dept Dermatol, Valencia, Spain
[9] Hosp Univ Sagrat Cor, Dept Dermatol, Grp Quironsalud, Barcelona, Spain
[10] Hosp Univ Vall dHebron, Dermatol Dept, Barcelona, Spain
[11] Hosp Univ Mutua Terrassa, Dermatol Dept, Terrassa, Spain
[12] Hosp St Caterina De Girona, Dermatol Dept, Girona, Spain
[13] Univ Autonoma Barcelona, Parc Tauli Hosp Univ, Cardiol, Sabadell, Spain
[14] Univ Autonoma Barcelona, Parc Tauli Hosp Univ, Inst Invest & Innovacio Parc Tauli I3PT CERCA, Paediat Unit, Sabadell 08208, Spain
[15] Parc Tauli Hosp Univ, Inst Invest & Innovacio Parc Tauli I3PT CERCA, Sabadell, Spain
[16] Hosp Gen Granollers, Dermatol Dept, Granollers, Spain
[17] Corp Sanitaria Parc Tauli Sabadell, Dept Dermatol, C Tauli 1, Sabadell 08208, Spain
关键词
D O I
10.1111/jdv.20044
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background and ObjectivesSurvival analyses can provide valuable insights into effectiveness and safety as perceived by prescribers. Here, we aimed to evaluate adalimumab (ADA) survival and the interruption risk factors in a multicentre cohort of patients with hidradenitis suppurativa (HS). Moreover, we performed a subanalysis considering the periods before and after the onset of the COVID-19 pandemic.MethodsWe conducted a retrospective study including 539 adult patients with HS who received ADA from 1 May 2015 to 31 December 2022. Overall drug survival was analysed using Kaplan-Meier survival curves and compared between the subgroups via stratified log-rank test. Possible predictors for overall drug survival and reasons for discontinuation were assessed using univariate and multivariate Cox regression.ResultsOverall, 50.1% were females with a mean age of 43.5 +/- 1 years and a mean BMI of 29.5 +/- 6.7. At the start of ADA, 95.29% were biologic-na & iuml;ve and 24.63% had undergone surgical treatment. During follow-up, 9.46% of patients required dose escalation, while 39.92% interrupted ADA. Concomitant therapy was used in 64.89% of cases. A subanalyses comparing pre- and post-pandemic periods revealed a tendency to initiate ADA treatment at a younger age, among patient with higher BMI and at a lower HS stage after COVID-19 pandemic. Interestingly, ADA demonstrated extended survival compared to previous studies, with a median overall drug survival of 56.2 months (95% CI 51.2 to 80.3). The primary causes for discontinuation were inefficacy (51.69%), followed by adverse effects (21.35%). Female sex, longer delay in HS diagnosis, higher baseline IHS4 score and concomitant spondyloarthritis were associated with poorer ADA survival or increased risk of discontinuation.ConclusionsADA demonstrated prolonged survival (median 56.2 months). While addition of antibiotics did not have a positive effect on survival rate, basal IHS4 proved useful in predicting ADA survival.
引用
收藏
页码:221 / 229
页数:9
相关论文
共 50 条
[41]   Severe hidradenitis suppurativa treated with adalimumab [J].
Moul, Danielle K. ;
Korman, Neil J. .
ARCHIVES OF DERMATOLOGY, 2006, 142 (09) :1110-1112
[42]   Hidradenitis Suppurativa and Ocular Diseases: Real-world Evidence of 57,972 Patients [J].
Von Stebut-Marx, Jennifer ;
Preissner, Robert ;
Schneider-Burrus, Sylke ;
Preissner, Saskia .
ACTA DERMATO-VENEREOLOGICA, 2025, 105
[43]   Clinical outcomes of secukinumab in moderate to severe hidradenitis suppurativa: Real-world response rates [J].
Roccuzzo, Gabriele ;
Repetto, Federica ;
Giordano, Silvia ;
Sarda, Cristina ;
Quaglino, Pietro ;
Ribero, Simone .
EXPERIMENTAL DERMATOLOGY, 2025, 34
[44]   Secukinumab Treatment in Patients with Hidradenitis Suppurativa in Real-World Clinical Settings: A Multicenter Study [J].
Erbagci, Ece ;
Bakay, Ozge Sevil Karstarli ;
Hapa, Fatma Asli .
DERMATOLOGY PRACTICAL & CONCEPTUAL, 2025, 15 (01)
[45]   Efficacy of adalimumab in recalcitrant hidradenitis suppurativa [J].
Sotiriou, Elena ;
Apalla, Zoe ;
Vakirlis, Eustratios ;
Ioannides, Demetrios .
EUROPEAN JOURNAL OF DERMATOLOGY, 2009, 19 (02) :180-181
[46]   Recalcitraxt hidradenitis suppurativa treated with adalimumab [J].
Ravat, F ;
O'Reilly, D ;
Handfield-Jones, S .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) :P58-P58
[47]   Adalimumab dose deintensification in hidradenitis suppurativa [J].
Cembrero Saralegui, Hirune ;
Alfageme Roldan, Fernando ;
Turrion Merino, Lucia ;
Cabeza Martinez, Rita ;
Elosua Gonzalez, Marta ;
Roustan Gullon, Gaston .
EXPERIMENTAL DERMATOLOGY, 2020, 29 :44-44
[48]   Real-world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: 12-week interim analysis of post-marketing surveillance in Japan [J].
Hayashi, Nobukazu ;
Hayama, Koremasa ;
Takahashi, Kenzo ;
Kurokawa, Ichiro ;
Okazaki, Masateru ;
Kashiwagi, Tomoko ;
Iwashita, Eri ;
Terui, Tadashi .
JOURNAL OF DERMATOLOGY, 2022, 49 (04) :411-421
[49]   Adalimumab for moderate to severe hidradentitis suppurativa: Real-world data from a tertiary clinic [J].
Sharif, Jennifer ;
Ferguson, Felicity J. ;
McMullen, Emma ;
Fitzgerald, David .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) :AB16-AB16
[50]   Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study [J].
Prens, L. M. ;
Bouwman, K. ;
Aarts, P. ;
Arends, S. ;
van Straalen, K. R. ;
Dudink, K. ;
Horvath, B. ;
Prens, E. P. .
BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (01) :177-184